VA
SRPT icon

Vident Advisory’s Sarepta Therapeutics SRPT Stock Holding History

Vident Advisory’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-10,642
Closed -$232K – 2030
2026
Q1 		$232K Sell
10,642
-1,913
-15% -$37K ﹤0.01% 1619
2025
Q4 		$270K Sell
12,555
-8,301
-40% -$175K ﹤0.01% 1413
2025
Q3 		$402K Buy
+20,856
New +$372K ﹤0.01% 1284
2025
Q2 		– Sell
-3,748
Closed -$239K – 1698
2025
Q1 		$239K Buy
3,748
+815
+28% +$85.8K ﹤0.01% 1361
2024
Q4 		$357K Buy
+2,933
New +$359K 0.01% 1104
2024
Q3 		– Sell
-2,100
Closed -$332K – 1542
2024
Q2 		$332K Sell
2,100
-19
-0.9% -$2.44K 0.01% 1088
2024
Q1 		$274K Sell
2,119
-180
-8% -$22K 0.01% 1082
2023
Q4 		$222K Buy
2,299
+265
+13% +$25.4K 0.01% 1167
2023
Q3 		$247K Buy
+2,034
New +$230K 0.01% 1017

Other funds holding SRPT

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
First Trust Advisors
First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $12.9B AUM 52.69% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Vident Advisory's SRPT Position: Q2 2026 in Review

Vident Advisory sold out of Sarepta Therapeutics (SRPT) in Q2 2026, closing a stake of 10,642 shares — an estimated $232K sold.

Vident Advisory first reported a position in SRPT in Q3 2023 and held it in 9 quarters. The position peaked at $402K in Q3 2025. 323 funds tracked by Wall St. Rank hold SRPT as of Q2 2026.

  • Vident Advisory reported no remaining Sarepta Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Vident Advisory sold 10,642 Sarepta Therapeutics shares in Q2 2026, an estimated $232K.
  • Vident Advisory first reported a position in Sarepta Therapeutics in Q3 2023 and held it in 9 quarters.
  • Vident Advisory's Sarepta Therapeutics position peaked at $402K in Q3 2025.
  • 323 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.